PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?

Samuel C Haywood; Shilpa Gupta; Hannelore V Heemers

doi:10.1016/j.euf.2022.08.010

PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?

Eur Urol Focus. 2022 Jul;8(4):916-918. doi: 10.1016/j.euf.2022.08.010. Epub 2022 Aug 26.

Authors

Samuel C Haywood¹, Shilpa Gupta², Hannelore V Heemers³

Affiliations

¹ Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
² Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
³ Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: heemerh@ccf.org.

Abstract

Emerging transcriptomics-based classifiers show promise as biomarkers to guide clinical decision-making in prostate cancer, but require further research, optimization, and validation.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Biomarkers, Tumor / genetics
Clinical Decision-Making
Humans
Male
Prognosis
Prostatic Neoplasms* / genetics
Transcriptome* / genetics

Substances

Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding